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Abstract Quality of botanical products is a great uncer-
tainty that consumers, clinicians, regulators, and researchers
face. Definitions of quality abound, and include specifica-
tions for sanitation, adventitious agents (pesticides, metals,
weeds), and content of natural chemicals. Because dietary
supplements (DS) are often complex mixtures, they pose
analytical challenges and method validation may be
difficult. In response to product quality concerns and the
need for validated and publicly available methods for DS
analysis, the US Congress directed the Office of Dietary
Supplements (ODS) at the National Institutes of Health
(NIH) to accelerate an ongoing methods validation process,
and the Dietary Supplements Methods and Reference
Materials Program was created. The program was con-
structed from stakeholder input and incorporates several
federal procurement and granting mechanisms in a coordi-
nated and interlocking framework. The framework facili-
tates validation of analytical methods, analytical standards,
and reference materials.
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Background
The Dietary Supplement Health and Education Act
(DSHEA) of 1994 (United States Public Law 103–417)
amended the Federal Food, Drug and Cosmetic Act by
defining as a dietary supplement any product (other than
tobacco) that contains a vitamin, mineral, herb or other
botanical, or amino acid and is intended as a supplement to
the diet [1]. The law also amended Title IV of the Public
Health Service Act by establishing the Office of Dietary
Supplements (ODS) within the Office of the Director, US
National Institutes of Health (NIH) (42 USC. 287c-3). The
mission of the ODS is to “strengthen knowledge and
understanding of dietary supplements by evaluating scien-
tific information, stimulating and supporting research,
disseminating research results, and educating the public to
foster an enhanced quality of life and health for the US
population.”
In the United States, the regulatory category into which
products fall is determined by the intended use of the
product. The DSHEAwas significant because it established
dietary supplements as a separate legal category and
defined a framework for Food and Drug Administration
(FDA) regulation of this category [2]. It also established the
regulatory framework for supplements as foods, not drugs,
set rules for what information labels must contain, and gave
FDA the authority to write supplement-specific Good
Manufacturing Practices (GMPs) based on a food model.
When the DSHEA became law in 1994, there were an
estimated 600 US dietary supplement manufacturers,
producing about 4,000 products [3]. According to Food
and Drug Administration estimates, there were more than
29,000 different dietary supplement products on the market
by the year 2000, with an average of 1,000 new products
being added annually [4]. Readers interested in an overview
of the pertinent regulations should consult Israelsen and
Barrett [5]. Growth of the marketplace was driven by
increased consumer demand, often following publicity
about the utility and efficacy of a particular herb. For
example, in 1996 Linde et al. [6] published a meta-analysis
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of randomized clinical trials of the herb St. John’s wort
(Hypericum perforatum L.) in the British Medical Journal
(BMJ), which concluded that the herb was more effective
than a placebo for treating certain types of mild-to-
moderate depression. A June 27, 1997 broadcast of the
television news magazine 20/20 (Using Herb St. John’s
Wort to Treat Depression) highlighted the BMJ article, and
sales of the herb increased rapidly. Other mainstream media
outlets quickly followed with articles on herbal medicine
[7, 8], and the entire industry grew quickly over the next
few years [9].
Later, the mainstream media began to take a closer look
at the subject of herbs. In 1998, the Los Angeles Times
commissioned a survey of St. John’s wort products
purchased from retail stores. The laboratory hired by the
newspaper was asked to measure the amount of the
phytochemical marker compound hypericin. The newspaper
reported that three of ten tested products contained no more
than 50% of the hypericin content declared on the label,
and that another four of ten contained less than 90% of the
label claim [10]. A later survey conducted by the Boston
Globe in 2000 reported similar results [11]. Publications in
the peer-reviewed scientific literature have also found
problems with quantitative label claims. Draves and Walker
observed that only two products (of 54) had a total
naphthodianthrone (hypericin) concentration within 10%
of the label claim [12]. Edwards and Draper examined
levels of berberine and hydrastine in 20 goldenseal
(Hydrastis canadensis) products and found that ten of
seventeen root products met alkaloid content standards
proposed by the United States Pharmacopeia (USP), and
that five products contained little or no hydrastine, unusual
berberine:hydrastine ratios, and additional peaks not ob-
served with other products [13]. Harkey et al. tested the
ginsenoside contents of 24 commercial ginseng products
and found that concentrations of marker compounds
differed significantly from labeled amounts [14].
In contrast to pharmaceutical products, there are fre-
quently several analytical methods available for the
determination of phytochemicals in botanical products. An
unpublished 2002 literature search performed for an AOAC
International review panel found 22 different methods for
constituents of St. John’s wort. Many of these methods
were based on different physical principles that would be
expected to lead to different numerical results for the target
constituents (e.g., spectrophotometry vs. chromatography).
A review of the scientific literature also reveals that
validation of methods within individual publications is
often lacking, as is cross-validation among methods. In the
absence of documentation of method performance,
researchers wishing to analyze a particular ingredient or
product are met with an abundance of methods whose
reliability is unknown or with no methods at all. As a result,
there are very few commonly accepted standard methods of
analysis available. Pharmacopoeial methods, where they
exist, may be of some help, but those methods are designed
to fit within a monograph “system,” and their limits of
applicability are often constrained. In this context, lack of
standard methods often leads investigators new to the field to
invent a method when they become interested in a particular
ingredient. This has led to the publication in peer-reviewed
journals of results that cannot be confirmed. The report of the
presence of colchicine in ginkgo and echinacea products
following discovery of this compound in the placental blood
of women who were consuming dietary supplements is an
example of this phenomenon [15], and repeated attempts to
reproduce those results have failed [16, 17].
Product quality
Product quality is one of the greatest question marks facing
consumers, clinicians, regulators, and researchers [18]. As
expected, there are some differences between definitions of
quality for herbal preparations and for chemically synthe-
sized products. Overall, fundamental quality parameters are
the same for both: identity, purity, and content determina-
tion (i.e., strength) [19]. The DSHEA does not set a
framework for quality except to state that manufacturers:
are prohibited from introducing products posing “signifi-
cant or unreasonable risk” into interstate commerce; must
get pre-market approval from FDA for “New Dietary
Ingredients;” must follow labeling regulations (accuracy,
label disclaimers, notification of claims); and must have
substantiation that claims are truthful and not misleading
[1]. Compliance with quality standards set out in official
compendia is voluntary. This lack of regulatory guidance
means that working definitions of quality within the
supplement industry vary, and quality parameters used by
individual companies in the US range from the simple to
the complex. For example, for some companies, quality is
ascertained by determining that the material was grown or
wildcrafted organically, that the correct plant species and
plant part (or extracts thereof) are present in the product,
and that the product has been manufactured in a sanitary
fashion (i.e., in compliance with GMPs [20]. Along with
identity criteria, other companies may set (or follow)
explicit specifications for microbial load, adventitious
agents (poisonous and otherwise), and content of desirable
and undesirable natural chemicals (see the USP, American
Herbal Pharmacopoeia (AHP), or European Pharmacopoeia
(EP)). Swanson [21] and NIH’s National Center for
Complementary and Alternative Medicine [22] have pro-
vided a useful overview of the types of parameters that
researchers and others should keep in mind when
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performing research or establishing quality assurance
procedures for botanicals.
Analytical challenges I
Analytical challenges in quality assurance range from
establishing the identity of the botanical source from which
an extract was derived to measuring the amount of one or
more desirable or undesirable natural constituents, such as
pesticides, toxic elements, natural toxins, or marker com-
pounds. Analytical methods are intended to generate
reliable, accurate data for use by manufacturers or regu-
lators for quality control or enforcement actions, respec-
tively. Reliability, accuracy, precision, and specificity are
the keys to the utility of a method, but analysts must take
steps to prove that any method they use has these features,
especially if the method is to be used in a critical setting
such as a quality control laboratory, a regulatory enforce-
ment action, or a clinical laboratory. However, there are
systematic approaches to demonstrating that a particular
method for a particular constituent yields accurate and
precise data.
Manufacturers need methods applicable throughout the
manufacturing process, while regulators require versatile
methods that can be used for the same analyte(s) in a
number of dissimilar finished products. The ability of a
particular method to fit the specified purpose is one element
of method validation that is important but often overlooked.
In addition to the difficulties noted above, botanicals are
complex mixtures that originate from biological sources.
Such products and their ingredients pose particular analyt-
ical challenges for a number of reasons, and method
validation has proven difficult. Raw materials are invariably
“irregular” because their chemical composition depends on
factors such as geographical origin, weather, harvesting
practices, etc., while finished products frequently contain
multiple botanical ingredients [23].
Over the past five decades or so, there has been an
evolution in the production, sale, and use of botanical
products. In the 1970s, botanical products were largely
sifted, cut, or powdered plant material in the form of a
tablet, capsule, tea, or tincture. More recently, products are
often carefully controlled extracts of plant material that
have been spray-dried onto a solid carrier or diluent and
then formed into a hard or soft capsule or tablet. There are a
number of advantages to such techniques. These include
savings in shipping costs as a result of reduced bulk, the
ability to produce dosage forms that are more uniform in
their composition, and the ability to preferentially concen-
trate the desirable constituents of a plant while leaving
behind undesirable constituents. The ability to affirm
identity and quality using simple and inexpensive tech-
niques such as microscopy or chemical spot testing are lost
when ingredients are processed and traded in this manner.
Globally, most countries have different regulatory
schemes to that of the US for therapeutic botanicals,
considering them a class of drugs (phytomedicines) rather
than a class of foods (dietary supplements). The EP defines
herbal drugs as “mainly whole, fragmented or cut, plants,
parts of plants, algae, fungi, lichen in an unprocessed state,
usually in dried form but sometimes fresh” [24]. Herbal
drugs are precisely defined by their Latin binomial name
(genus, species, variety, and author), and are identified
using their macroscopic and microscopic descriptions and
any further tests that may be required (for example, thin-
layer chromatography). The EP monographs for herbal
drugs contain less detailed specifications than one might
expect and depend heavily on descriptive botany (micro-
and macro-anatomy) with some rudimentary chemistry
when necessary. Herbal drug monographs include those
for some familiar plants, including St. John’s wort, ginkgo
leaf, ginseng root, elder flower, equisetum stem, and others.
The raw material extract feed stocks used in the
preparation of commercial phytomedicines are termed
“herbal drug preparations” by the EP [25]. These materials
are obtained by subjecting herbal drugs to treatments such
as extraction, distillation, expression, fractionation, purifi-
cation, concentration, or fermentation. The physical form of
an “extract” in the marketplace may vary. They may occur
as liquids (liquid extracts and tinctures), semi-solids (soft
extracts), or solids (dry extracts). Standardized extracts are
those that have been adjusted within an acceptable
tolerance to a given content of constituents with known
therapeutic activity. Standardization is achieved by adjust-
ing the extract with inert material or by blending batches of
extracts. Examples of EP-standardized extracts are Ipeca-
cuanha liquid extract, standardized Belladonna leaf dry
extract, standardized senna leaf dry extract, standardized
licorice ethanolic liquid extract, standardized Frangula bark
dry extract, and standardized aloes dry extract (made from
Aloe ferox Miller and its hybrids and A. barbadensis
Miller). Note that extracts of many well known herbs such
as St. John’s wort are not considered to be standardized
extracts in the EP because the “active” constituents are
unknown. To account for extracts for which the true active
constituents are unknown, the EP has defined “quantified
extracts” as those adjusted to a defined range of constitu-
ents (marker compounds) that may or may not be
therapeutically active, but that are not now “known” to be
responsible for the therapeutic activity of the plant [25].
As noted, the use of well-defined extracts aids in the
production of a reproducible and uniform product, and the
definition of “standardization” published by the American
Herbal Products Association recognizes that it is possible to
manufacture a standardized extract without knowing the
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therapeutically active constituent(s) [26]. Marker com-
pounds are constituents of a plant selected as surrogate
indicators of “quality” by manufacturers and/or researchers
because they are thought to be unique to the target plant
species (and therefore are an aid to plant identification) or
because they are thought to be associated with the
biological activity of the plant. Continuing research has
overturned such assumptions in a number of cases. For
instance, the napthodianthrone, hypericin, was once thought
to be unique to St. John’s wort Hypericum perforatum L.
and was a good species identifier. An early in vitro assay of
St. John’s wort and hypericin also indicated that the
compound was a monoamine oxidase inhibitor. More recent
studies have proposed that hyperforin and/or a series of
flavonol glycosides also contribute to the beneficial
antidepressant activity of the herb [27] as well as to
potential herb/drug interactions [28, 29].
Analytical challenges II
In the United States, systematic evaluations of botanical
products are in their infancy. The main drivers of
biomedical research in this area are taxpayer-funded trials
conducted under the aegis of the U.S. National Institutes of
Health. Two recent publications have highlighted the
importance of product quality determination and the need
to define and describe the nature of interventions to be used
in biomedical research. Over the past decade, several
authors have published scales for evaluating the quality of
published clinical trials that assess the reliability of the
conclusions drawn from those trials so that evidence-based
standards of medical care may be developed. These systems
include the Jadad scale [30] and the Consolidated Standards
of Reporting Trials Statement (CONSORT) [31]. The best
trials are considered randomized, placebo-controlled, dou-
ble-blind studies, but variations between trial designs and
their descriptions still allow for nominally similar designs
to vary in quality. Elements of these rating systems allow
readers to rate the strengths of individual trial designs.
Items such as sample size, intent-to-treat analysis, degree
and adequacy of blinding (single-blind, double-blind), and
randomization scheme (and the means of achieving
randomization) were assigned numerical scores from worst
to best. Trials with good overall scores are said to be less
biased. These rating systems were designed with a focus on
the mechanics of the clinical trial itself and assumed that
the interventions used in the trials had been well character-
ized. In 2005, Gagnier et al. [32] recognized that in the
emerging field of biomedical research on natural products,
adequate characterization and description of the interven-
tion was not always present in trial publications, and they
proposed a revised CONSORT Statement that includes
scoring for the quality of the description of the intervention.
As a result of the growing realization of the nature and
extent of this problem, Wolsko et al. [33] performed a
systematic evaluation of the literature of herbal clinical
trials in order to quantify the reliability of the clinical
botanical literature in terms of product quality. A review of
81 studies found that only 12 of the 81 (15%) reported
having performed quantitative analysis on the intervention.
Of these, only eight reported results of the analyses. The
authors also reported that only 40 of the 81 botanical
studies (49%) identified the plant source of the intervention
by Latin name (recall the discussion on “Herbal Drugs”
presented earlier). Only eight (10%) of the studies
identified the plant part used in the study, and only 23
(28%) of the studies described the extraction/processing
method used to prepare the study intervention. In 2006,
Gagnier et al. [34] published an extensive review of 206
randomized controlled trials of herbal medicines and scored
them against 42 separate CONSORT checklist items. A
detailed description of the results is not within the scope of
this discussion, but only 54% of the reviewed trials provide
a precise description of the intervention. As a result of the
marketplace problems noted in the “Introduction” and these
more recent concerns about the quality of recent natural
products trials, the National Center for Complementary and
Alternative Medicine (NCCAM) at NIH has instituted a
policy that requires grant applicants to demonstrate to
NCCAM and grant reviewers that the materials to be used
in NCCAM-funded research are adequately characterized
and described [22]. Investigators have struggled to fulfill
this mandate as they have discovered that there are few
reliable published analytical methods and reference materi-
als available.
Role of the Office of Dietary Supplements
The DSHEA empowered the FDA to establish current good
manufacturing practices (GMPs) for dietary supplements,
and a proposed rule has been published [19]. The law
requires that any enforcement action taken against dietary
supplement products use “publicly available” methods. In
response to concerns about the lack of properly validated
publicly available methods and general concerns about
product quality, the US Congress directed the Office of
Dietary Supplements (ODS) at NIH to accelerate an
ongoing method validation process [35].
The ongoing process has been a collaboration between
AOAC International (Gaithersburg, MD, USA) and various
stakeholder groups, including representatives of the dietary
supplement industry, regulatory and other governmental
bodies, consumer groups, nongovernmental organizations,
and research scientists. The ODS program began with a
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meeting held to identify needs that might be met by the new
program. Stakeholders advised ODS that the new program
should emphasize basic quality issues such as identity and
contamination and should use existing frameworks for
method development and validation [36]. The program
itself began by providing funds to the FDA’s Center for
Food Safety and Applied Nutrition (CFSAN) for the
purpose of validating analytical methods through the
AOAC Official MethodsSM program. Under the auspices
of the ODS program, the AOAC/stakeholder collaboration
identified supplement ingredients for study and set priori-
ties for the order in which they would be pursued.
Following prioritization, available analytical methods col-
lected by the group were subjected to an “NIH-style” peer
review process for the purpose of selecting the most
promising methods for further study. To date, nine
supplement methods have been collaboratively studied,
with seven approved as first action Official Methods.
Collaborative study reports have been published for five
of the approved methods (ephedrine alkaloids in botanicals/
dietary supplements by HPLC/UV [37], ephedrine alkaloids
in plasma/urine by LC–MS [38], glucosamine in raw
materials and finished products [39], beta-carotene in raw
materials and finished products [40], flavonol glycosides in
Ginkgo biloba raw materials and finished products [41].
Collaborative study manuscripts are in press for “Phytos-
terols in Saw Palmetto raw materials and finished products”
and for “Aristolochic acid in raw materials and finished
products.” Single-laboratory validation studies of these
methods have been published [42, 43]. There are an
additional nine single-laboratory validation studies in
progress, and 38 additional ingredients in various stages
of study. These include S-adenosyl-L-methionine (SAMe),
chondroitin sulfate, St. John’s wort,L-carnitine, B vitamins,
black cohosh, Ω-3 fatty acids, soy isoflavones, green tea
catechins, lutein, turmeric, ginger, milk thistle, African
plum, and flax seed.
In addition to progress on Official Methods, the past
five years have seen the emergence of a community of
analytical chemists, dietary supplement researchers, and
others concerned with dietary supplement analytical meth-
odology. In the two years before the launch of the ODS
program, there were no dietary supplement publications in
the Journal of AOAC International. Between the launch of
the program in 2002 and the present, there have been over
100 dietary supplement methods published in the journal.
Some method development work is being performed by
the Food Composition Laboratory at the United States
Department of Agriculture (USDA) through an interagency
agreement with ODS. The USDA agreement will result in
the development of analytical methods for phenolic glyco-
sides in foods and supplements. In addition, ODS has
recently entered into agreements with experts at the FDA’s
CFSAN to develop or extend validated methods for the
determination of mycotoxins, pesticides, and toxic elements
in dietary supplement raw materials and finished products.
Stakeholders identified three distinct needs in regard to
reference materials. First was the need for biological
reference materials to be used for botanical identity
confirmation. This effort has been hampered by a number
of technical issues, not least of which is defining the nature
of such materials. The second need was for the production
and dissemination of calibration standards needed for the
development, validation, and routine use of supplement
methods. Calibration standards are the single chemical
entities needed to construct calibration curves for quantita-
tive analysis and analyte identity confirmation. With some
exceptions, the high cost of well characterized high purity
plant secondary metabolites for use as calibration standards
has been a major impediment to method development and
validation. The usual practice used by researchers who
needed to make an analytical measurement of a plant
constituent was for the individual investigator to isolate
pure compounds from the plant of interest and use that
material in the investigation. This process is time-consum-
ing, expensive, gives low yields, and is limited to the
laboratory of the individual researcher. In addition, the
compounds may also be unstable in pure form. In order to
expedite the development and validation of methods, ODS
has sponsored research into small- to medium-scale
isolation methods for the production of pure compounds
as well as the acquisition of these compounds for use in
collaborative studies. It has also sponsored research into
methods for stabilizing labile compounds. While quantities
of the materials produced for collaborative studies are large
by historical standards, they remain quite small in market-
place terms. ODS has therefore funded the production of
larger quantities of very high purity standards for national
standard-setting bodies, such as the USP. To date, the
program has contracted for the production of: berberine
hydrochloride, hydrastine, beta-sitosterol, gingerol, shoa-
gol, actein, 27-deoxyactein, and eleutherosides B and E as
USP reference materials. Approximately 20 other materials
have also been produced for use in collaborative and pre-
collaborative studies, including a stabilized hyperforin
material in a liquid format and anthocyanin standards for
various Vaccinium species.
The final need was for matrix reference materials. This
part of the ODS program has been conducted in partnership
with the National Institute of Standards and Technology
(NIST) in the US Department of Commerce. One of the
most important features of any analytical testing protocol is
the ability of the analyst to verify whether or not the
analytical instrument is operating properly and whether the
assay has been performed correctly. A useful ways to make
this determination is to perform the method on a material
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that has had values for the analyte of interest assigned to it
through a formal certification process. If the analyst
succeeds in reproducing the certified values, then he or
she can be confident that the analysis was performed
properly. These materials are used when evaluating analyt-
ical method performance in individual laboratory settings
and are useful tools in laboratory proficiency testing.
Briefly, the NIST materials are produced as suites of
supplement raw materials and finished products for
which certified values for selected chemical constituents
are established using a rigorous standard approach. Each
suite consists of properly identified dried, powdered
botanical raw material, a commercial raw material
extract, and one or more representative commercial
products. The NIST process involves obtaining authentic
botanical raw material, developing and validating analyt-
ical methods (if none exist) to determine the compounds
to be certified, using two or more methods and
laboratories to analyze for the compounds of interest,
and assigning values to be written into a Certificate of
Analysis [44]. Materials are then packaged appropriately
and made available for purchase. There are currently 15
suites of NIST Standard Reference Materials (SRMTM) in
process, with five (Ephedra, Ω-3 fatty acids in cod liver oil,
ginkgo biloba, β-carotene in carrot oil, and multivitamin/
multimineral tablets) now available. Those in process are
bitter orange, saw palmetto, α-tocopherols, green tea,
various vaccinium berries, Ω-3 fatty acids in seed oils,
and vitamins D, B6, and B12 in serum. Acquisitions in
progress are soy, St. John’s wort, and black cohosh [45].
Additional projects include funding of single-laboratory
validation studies of ingredients that are deemed important
by NIH or FDA but that are not highly ranked by the
AOAC stakeholder committee process (e.g., constituents of
bitter orange [46], aflatoxins in botanicals [47], as well as a
study validating thin-layer chromatographic fingerprinting
methods for determining botanical identity. This latter
project is in keeping with stakeholder recommendations
about pursuing methods for verifying plant identity, and is
complemented by funding for an electronic herbarium pilot
project and for the production of a handbook of botanical
microscopy to replace the botanical drug microscopy texts
of the late nineteenth and early twentieth century. An
additional project related to plant identification is the
development of a system for the identification, isolation,
and characterization of compounds in plants that may
indicate the presence of undesirable plant species (adulter-
ants) in the botanical raw material or finished product.
Identification of these “negative marker” compounds by
bioassay-directed fractionation will be followed by the
development and validation of analytical methods for these
compounds.
Conclusion
An enormous challenge remains in developing, validating,
and disseminating methods and reference materials for the
40,000 supplement products projected to be on the US market
by 2010 [4]. Acceleration and expansion of the program will
continue as the supplement analytical community grows.
Recognition of new opportunities has already begun to
reshape the program. Beginning in 2007, there will be an
increasing emphasis on funding single-laboratory validation
studies and on performance-based analytical methods. Part of
this shift is made possible by an ODS-funded laboratory
proficiency pilot program administered by NIST, but the
emphasis on rapid dissemination and small-scale laboratory
studies were both key recommendations made by stake-
holders at the beginning of the program [36].
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